Access the full text.
Sign up today, get DeepDyve free for 14 days.
Y. Cossart (2004)
Human Parvovirus B19American Journal of Transplantation, 4
I. Schmidt, Johannes Blümel, H. Seitz, H. Willkommen, Johannes Löwer (2001)
Parvovirus B19 DNA in plasma pools and plasma derivativesVox Sanguinis, 81
S. Shimomura, N. Komatsu, N. Frickhofen, S. Anderson, S. Kajigaya, N. Young (1992)
First continuous propagation of B19 parvovirus in a cell line.Blood, 79 1
B. Schneider, M. Becker, H. Brackmann, A. Eis-Hübinger (2004)
Contamination of coagulation factor concentrates with human parvovirus B19 genotype 1 and 2Thrombosis and Haemostasis, 92
Young Young, Brown Brown (2004)
Parvovirus B19N Engl J Med, 350
(2008)
Risk of parvovirus infection by immunoglobulin
(2005)
Phase IV Study of Plas + SD : hepatitis A ( HAV ) and parvovirus B 19 ( B 19 ) safety results
J. Blümel, A. Eis-Hübinger, A. Stühler, Claudia Bönsch, M. Gessner, J. Löwer (2005)
Characterization of Parvovirus B19 Genotype 2 in KU812Ep6 CellsJournal of Virology, 79
J. Feldschuh, Y. Enson (1977)
Prediction of the Normal Blood Volume: Relation of Blood Volume to Body HabitusCirculation, 56
K. Ozawa, J. Ayub, Y. Hao, G. Kurtzman, T. Shimada, N. Young (1987)
Novel transcription map for the B19 (human) pathogenic parvovirusJournal of Virology, 61
Y. Cossart, B. Cant, A. Field, D. Widdows (1975)
PARVOVIRUS-LIKE PARTICLES IN HUMAN SERAThe Lancet, 305
P. Caillet-Fauquet, M. Giambattista, Marie-Louise Draps, V. Hougardy, Y. Launoit, R. Laub (2004)
An assay for parvovirus B19 neutralizing antibodies based on human hepatocarcinoma cell linesTransfusion, 44
J. Blümel, I. Schmidt, H. Willkommen, J. Löwer (2002)
Inactivation of parvovirus B19 during pasteurization of human serum albuminTransfusion, 42
K. Brown, N. Young, B. Alving, L. Barbosa (2001)
Parvovirus B19: implications for transfusion medicine. Summary of a workshopTransfusion, 41
Henry Nider (1989)
Report of the Committee on Infectious DiseasesArchives of Dermatology, 125
(2000)
Parvovirus B 19 : implications for
Quang Nguyen, C. Sifer, V. Schneider, Xavier Allaume, A. Servant, F. Bernaudin, Véronique Auguste, A. Garbarg‐Chenon (1999)
Novel Human Erythrovirus Associated with Transient Aplastic AnemiaJournal of Clinical Microbiology, 37
F. Bonvicini, G. Gallinella, M. Cricca, S. Ambretti, S. Delbarba, M. Musiani, M. Zerbini (2004)
Molecular testing for detection of in vitro infectivity of plasma pools contaminated with B19 virusJournal of Medical Virology, 74
Quang Nguyen, Susan Wong, E. Heegaard, K. Brown (2002)
Identification and characterization of a second novel human erythrovirus variant, A6.Virology, 301 2
Grigori Prikhod’ko, I. Vasilyeva, H. Reyes, Susan Wong, K. Brown, T. Jameson, T. Busby (2005)
Evaluation of a new LightCycler reverse transcription–polymerase chain reaction infectivity assay for detection of human parvovirus B19 in dry‐heat inactivation studiesTransfusion, 45
S. Apfelroth (2000)
Viral safety of solvent/detergent‐treated plasmaTransfusion, 40
S. Pankuweit, V. Ruppert, H. Eckhardt, D. Strache, Bernhard Maisch (2005)
Pathophysiology and aetiological diagnosis of inflammatory myocardial diseases with a special focus on parvovirus B19.Journal of veterinary medicine. B, Infectious diseases and veterinary public health, 52 7-8
T. Pumarola (1995)
[Parvovirus B19].Medicina clinica, 104 1
M. Regenmortel (2000)
Virus taxonomy: classification and nomenclature of viruses. Seventh report of the International Committee on Taxonomy of Viruses.
Pharmeurope, 14
D. Candotti, N. Etiz, Armen Parsyan, J. Allain (2004)
Identification and Characterization of Persistent Human Erythrovirus Infection in Blood Donor SamplesJournal of Virology, 78
Annapolis (MD): Plasma Protein Therapeutics Association
M. Yunoki, T. Urayama, M. Tsujikawa, Y. Sasaki, S. Abe, K. Takechi, K. Ikuta (2005)
Inactivation of parvovirus B19 by liquid heating incorporated in the manufacturing process of human intravenous immunoglobulin preparationsBritish Journal of Haematology, 128
Susan Wong, K. Brown (2006)
Development of an improved method of detection of infectious parvovirus B19.Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 35 4
P. Daly, A. Corcoran, Bernard Mahon, Sean Doyle (2002)
High-Sensitivity PCR Detection of Parvovirus B19 in PlasmaJournal of Clinical Microbiology, 40
L. Liefeldt, A. Plentz, B. Klempa, O. Kershaw, A. Endres, U. Raab, H. Neumayer, H. Meisel, S. Modrow (2005)
Recurrent high level parvovirus B19/genotype 2 viremia in a renal transplant recipient analyzed by real‐time PCR for simultaneous detection of genotypes 1 to 3Journal of Medical Virology, 75
M. Yunoki, M. Tsujikawa, T. Urayama, Y. Sasaki, M. Morita, H. Tanaka, S. Hattori, K. Takechi, K. Ikuta (2003)
Heat sensitivity of human parvovirus B19Vox Sanguinis, 84
Heegaard Heegaard, Brown Brown (2002)
Human parvovirus B19Clin Microbiol Rev, 15
J. Kerr, H. O'neill, R. Deleys, C. Wright, P. Coyle (1995)
Design and production of a target-specific monoclonal antibody to parvovirus B19 capsid proteins.Journal of immunological methods, 180 1
Eiji Miyagawa, T. Yoshida, Hirohiko Takahashi, K. Yamaguchi, Tohko Nagano, Yoshiko Kiriyama, Kazuo Okochi, Hiroyuki Sato (1999)
Infection of the erythroid cell line, KU812Ep6 with human parvovirus B19 and its application to titration of B19 infectivity.Journal of virological methods, 83 1-2
A. Eid, Robert Brown, Robin Patel, R. Razonable (2006)
Parvovirus B19 infection after transplantation: a review of 98 cases.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 43 1
BACKGROUND: Human parvovirus B19 (B19V) is a highly prevalent pathogen, and plasma pools for manufacturing of plasma‐derived products have been shown to contain antibodies against B19V (B19V immunoglobulin G (IgG)). STUDY DESIGN AND METHODS: The megakaryoblastic cell line UT7/Epo‐S1 can be infected with B19V Genotype 1 and as demonstrated here by immunocytochemistry, Western blot, and reverse transcription–polymerase chain reaction (RT‐PCR) of B19V‐specific mRNA, also with the more recently discovered Genotype 2. Based on B19V RT‐PCR analysis of infected UT7/Epo‐S1 cells, an infectivity assay was established and implemented for a B19V neutralization assay. To investigate the role of B19V neutralization in relation to B19V IgG titers, more than 1000 manufacturing plasma pools were tested by enzyme‐linked immunosorbent assay. RESULTS: Plasma pools were found to contain a mean B19V IgG titer of 33 ± 9 IU per mL, with the lowest titer at 11 IU per mL. These 11 IU per mL B19V IgG neutralized 4.6 log B19V Genotype 1 and greater than 3.9 log Genotype 2 infectivity. Accordingly, a 10 percent intravenous immunoglobulin (IVIG) product prepared from such pools was found to contain an even higher B19V neutralization capacity. CONCLUSION: A high capacity of B19V Genotypes 1 and 2 neutralization was demonstrated in plasma pools for fractionation, an inherent feature based on the constantly high titer of B19V IgG in these pools. The neutralizing activity of B19V IgG was shown to be maintained in the 10 percent IVIG product tested.
Transfusion – Wiley
Published: Jan 1, 2008
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.